ZyVersa Therapeutics Inc.

0.60
0.01 (2.13%)
At close: Apr 02, 2025, 3:58 PM
0.61
1.90%
After-hours: Apr 02, 2025, 07:50 PM EDT

ZyVersa Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Revenue n/a n/a n/a n/a n/a
Cost of Revenue n/a 10.4K 10.4K 10.4K 10.4K
Gross Profit n/a -10.4K -10.4K -10.4K -10.4K
Operating Income -9.14B -14.42M -13.01M -7.7M -11.83M
Interest Income n/a n/a 427.54 821.37 516.45
Pretax Income -9.42B -107.75M -14.05M -8.08M -12.68M
Net Income -9.41B -98.3M -759.1M -8.91M -13.2M
Selling & General & Admin 7.36B 11.2M 7.61M 5.58M 5.36M
Research & Development 1.78B 3.21M 5.41M 2.12M 6.47M
Other Expenses n/a n/a n/a n/a n/a
Operating Expenses 9.14B 14.41M 13.01M 7.7M 11.83M
Interest Expense 269.86M -457K 427.54K 821.37K 516.45K
Selling & Marketing Expenses n/a -11.2B n/a n/a n/a
Cost & Expenses n/a 14.42M 13.01M 7.7M 11.83M
Income Tax -6.75M -9.46M 745.05M 821.37K 516.45K
Shares Outstanding (Basic) 11.1M 97.5K 25.95K 46.55K 46.55K
Shares Outstanding (Diluted) 11.1M 97.5K 25.95K 46.55K 46.55K
EPS (Basic) -848.03 -1.09K -930.25 -173.66 -272.45
EPS (Diluted) -848.03 -1.09K -930.25 -173.66 -272.45
EBITDA -9.14B -107.74M -11.67M -7.25M -12.16M
EBIT -9.15B -107.75M -14.44M -7.26M -12.17M
Depreciation & Amortization n/a 10.4K 10.4K 10.4K 10.4K